- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Remedy for the treatment of gout.
The anti-gout effect of colchicine is associated with a decrease in leukocyte migration to the focus of inflammation and inhibition of phagocytosis of uric acid salt microcrystals. It also has an antimitotic effect, inhibits (fully or partially) cell division in the anaphase and metaphase stages, prevents neutrophil degranulation. Reducing the formation of amyloid fibrils, prevents the development of amyloidosis.
Highly effective for relieving acute gout. In the first 12 hours of therapy, the condition significantly improves in more than 75% of patients. 80% can cause adverse reactions from the gastrointestinal tract before clinical improvement or at the same time.
At a daily dose of 1-2 mg when taken daily in 3/4 patients with gout reduces the likelihood of recurrent acute attacks.
Warns acute attacks in patients with familial Mediterranean fever (lowers dopamine-beta-hydroxylase activity).
Increases the life expectancy of patients with primary AL amyloidosis.
It has a positive effect on the skin (softening, reducing dryness) with systemic scleroderma.
Colchicine is rapidly and rapidly absorbed from the gastrointestinal tract. The average maximum plasma concentration is 4.2 ng / ml and is reached approximately 70 minutes after administration at a dose of 1 mg. The half-life is 9.3 hours. Colchicine quickly penetrates the tissue, has a high volume of distribution of 473 liters. High concentrations of colchicine are found in the liver, kidneys, spleen, leukocytes and gastrointestinal tract. Colchicine is metabolized in the liver and excreted mainly with bile.
Enterohepatic circulation is detected 4-6 hours after oral administration. The largest part of the injected dose is excreted through the intestines and about 23% through the kidneys.
Acute gout attacks.
Prevention of acute attacks of gout in combination with uricosuric drugs.
Periodic illness (familial Mediterranean fever).
To avoid complications, use only after consulting a doctor.
1 coated tablet contains:
Active ingredient: Colchicum autumn seed extract [eq. 500 mcg of colchicine] [in the composition of the extract 57-64% lactose, 28-32% microcrystalline cellulose] 15.6 mg;
Copovidone 5.33 mg
Corn starch 27.5 mg
Lactose monohydrate 41.6-43.9 mg
Magnesium stearate 0.33 mg
Palmitostearic acid 1.34 mg
Talc 7.00 mg
Microcrystalline cellulose 3.6-5.2 mg
Acacia gum 0.3 mg
Carnauba wax 0,140 mg
Carmellose sodium 0,273 mg
Magnesium oxide 2.6 mg
Macrogol 6000 1,093 mg
Opalux AS 250000
[sucrose - 0,7923 mg
Ponso 4R (E124) - 0.26334 mg,
yellow (Е104) - 0.09652 mg,
titanium dioxide (E171) 0.07904 mg,
Povidone 0.0133 mg] 1.2445 mg
Povidone - K 25 2.186 mg
Sucrose 86.1515 mg
Talc 11, 975 mg
Titanium dioxide (E171) 3.717 mg
Shellac 0.32 mg
No customer reviews for the moment.
Dosage and Administration
In the case of an acute gout attack, first take 2 dragees with sugar coating (1 mg of colchicine), and then 1–3 dragees (0.5–1.5 mg of colchicine) every 1–2 hours until the pain subsides. The total dose of the drug taken per day should not exceed 16 pills (8 mg of colchicine). For the prevention of acute attacks of gout in the first few months of treatment with uricosuric drugs take 1-3 pills with sugar coating (0.5-1.5 mg of colchicine) daily or every other day, usually for 3 months.
Sugar coated dragees are swallowed whole, not chewed and squeezed with a sufficient amount of liquid.
Repeated treatment of an acute attack of gout can be carried out no earlier than after 3 days.
Diarrhea, nausea, vomiting and stomach pain may occur. Rare cases of leukopenia (a decrease in the number of white blood cells) have been reported. In some cases, after long-term treatment, myoneuropathy (weakness of muscles and nerve tissues) was observed, less often agranulocytosis, hypoplastic anemia (change in the number of blood corpuscles), skin changes and alopecia (baldness).
Hypersensitivity, pregnancy, lactation, hepatic and / or renal failure, pronounced inhibition of bone marrow hematopoiesis.
Lactose intolerance, lacgas deficiency, sucrase / isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption. Children's age up to 18 years.
Patients with diabetes (due to the content of sucrose and lactose in the composition of the drug).
In combination with cyclosporine, especially in patients with impaired kidney function, the likelihood of myopathy increases.
Enhances the effect of depriming and sympathomimetic drugs.
Violates the absorption of cyanocobalamin.
Non-steroidal anti-inflammatory drugs and other drugs that cause myelodepression increase the risk of leukopenia and thrombocytopenia.
Anti-gout activity is reduced by cytostatics (increases the concentration of uric acid) and acidifying preparations of urine, which alkalize, enhance the effect.
Kolhikum-Dispert® can be used in combination with allopurinol and preparations of uricosuric action.
Pregnancy and Lactation
Kolkhikum-Dispert® is contraindicated during pregnancy and lactation.
Treatment should be carried out under careful hematological and clinical control.
With the appearance of pronounced side effects from the gastrointestinal tract, reduce the dose or discontinue the drug.
With a decrease in the number of leukocytes below 3000 / μl and platelets below 100000 / μl, the administration is stopped until the blood picture is normalized.
Impact on the ability to drive trans. Wed and fur .:
Does not affect.
Acute intoxication was observed in adults after taking a dose of about 20 mg and in children after taking a dose of 5 mg.
Chronic intoxication can be observed in patients with gout after taking a total dose of 10 mg or more for several days.
Since colchicine has antimitotic activity, organs that are characterized by a high proliferation rate are more often affected.
- Brand name: Kolhikum Dispert
- Active ingredient: Colchicine
- Dosage form: Dragee
- Manufacturer: Abbott
- Country of Origin: USA
- Colchicine affects cortical and amygdalar neurochemical changes differentially after middle cerebral artery occlusion in rats
- Role of P-170 glycoprotein in colchicine brain uptake
- Myotonia in colchicine myoneuropathy
- Colchicine-induced myopathy with myotonia
- Colchicine-induced myopathy with myotonia (A reply)
- Dentate gyrus-selective colchicine lesion and disruption of performance in spatial tasks: Difficulties in “place strategy” because of a lack of flexibility in the use of environmental cues?
- Colchicine poisoning: report of a fatal case with body fluid and post-mortem tissue analysis by high-performance liquid chromatography
- Comparative Study of Colchicine and Trimethylcolchicinic Acid on Prolonged Bile Duct Obstruction in the Rat
- Induction of lysosomal abnormalities and tau hyperphosphorylation in human neuroblastoma cells by colchicine and okadaic acid: Evidence that microtubule disruption contributes to alzheimer neurodegeneration
- Preferential sensitivity of acrocentric chromosomes to the aneugenic effect of colchicine
- The Absolute Configuration of Colchicine by Correct Application of the CIP Rules
- Studies on colchicine derivatives. I. Toxicity in mice and effects on mouse sarcoma 180
- Studies on colchicine derivatives. II. Effect on mitotic activity of the corneal epithelium
- Studies on colchicine derivatives. III. Effect on mitotic activity of mouse spermatogonia
- Colchicine. III. Pathology and hematology in cats and rats
- Bone marrow depression associated with acute colchicine toxicity in the presence of hepatic dysfunction
- Cytology and colchicine sensitivity of viable cells from lymph nodes with malignant lymphoma
- Clinical and cellular effects of colchicine in fibromatosis
- Mechanism of colchicine-induced steroidogenesis in rat adrenocortical cells
- Facile Construction of the Colchicine Skeleton By a Rhodium-Catalyzed Cyclization/Cycloaddition Cascade
- Complexation and ionophoric properties of taxol and colchicine: complex formation and transport of sodium, potassium, magnesium and calcium ions across a liquid membrane
- Colchicine analogs in the treatment of acute gout
- Skin Elasticity and Colchicine in Scleroderma